In total, AstraZeneca will pay $1 billion, plus an additional $200 million upon the achievement of specific regulatory requirements.
It is anticipated that the deal would finalize in 2024’s first quarter. The Swedish-British business hopes to improve its standing in the field of autoimmune and cancer cell treatment through it.
AstraZeneca will acquire Gracell as a 100% subsidiary, and Gracell will operate in both China and the US.
source: bloomberg.com
